Physician profile
Allison Marie Simms
NPI 1801137633
$3,147.86
in general payments reported to CMS, 2019-2025
34 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $141 · 2021: $551 · 2022: $535 · 2023: $350 · 2024: $867 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $957.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $186.03 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.93 | 2022-2024 | |
| Lilly USA, LLC | $150.02 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $143.07 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $122.62 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $119.36 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $99.95 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $94.97 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $93.24 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.75 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $79.57 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $70.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.53 | 2022-2025 | |
| Inspire Medical Systems, INC. | $65.54 | 2024-2025 | Inspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.60 | 2021-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $62.50 | 2022-2025 | Gvoke Hypopen |
| Lundbeck LLC | $55.82 | 2021-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.81 | 2021-2024 | Ofev |
| Merck Sharp & Dohme LLC | $50.10 | 2019-2022 | |
| Edwards Lifesciences Corporation | $46.34 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $46.13 | 2022 | |
| Nevro Corp. | $43.85 | 2023-2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $41.87 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $38.98 | 2022-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.11 | 2024 | Xifaxan |
| Seqirus USA INC | $19.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.70 | 2021 | |
| Medtronic, INC. | $17.31 | 2025 | Minimed 780g |
| Boston Scientific Corporation | $16.13 | 2024 | |
| Irhythm Technologies, INC. | $15.85 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $15.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.29 | 2024 | Voquezna |
| Medtronic Minimed, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.